The results also demonstrated a significant locus‐dosage effect in patients with a larger number of unfavorable genotypes, who had a shorter DFS, suggesting an interaction of SMAD3 rs11556090 and RBL2 rs3929 in the cell cycle pathway on HCC progress. Here, SMAD3 is linked to hepatocellular carcinoma.